Pathogen-host interactions in pseudomonas aeruginosa pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 11, 2005, Pages 1209-1223

  Sadikot, Ruxana T ^a   Blackwell, Timothy S ^a   Christman, John W ^b   Prince, Alice S ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Illinois at Chicago ^*  (United States)

Author keywords

Cystic fibrosis; Cytokines; Epithelium; Host defense; Nosocomial

Indexed keywords

REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SURFACTANT ASSOCIATED PROTEIN; SYNDECAN;

ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL GENETICS; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DISEASE ASSOCIATION; GRAM NEGATIVE INFECTION; HISTOPATHOLOGY; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; LUNG INFECTION; LUNG INJURY; LUNG PARENCHYMA; MACROPHAGE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; T LYMPHOCYTE; VENTILATOR ASSOCIATED PNEUMONIA;

ACUTE DISEASE; CHRONIC DISEASE; CROSS INFECTION; CYSTIC FIBROSIS; HOST-PARASITE RELATIONS; HUMANS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 19644371239     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200408-1044SO     Document Type: Review

References (220)

1. Richards M, Edwards J, Culver D, Gaynes R. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-892.
2. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122:2183-2196.
3. Chastre J, Fragon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
4. Leibovitz A, Dan M, Zinger J, Carmeli Y, Habot B, Segal R. Pseudomonas aeruginosa and the oropharyngeal ecosystem of tube-fed patients. Emerg Infect Dis 2003;9:956-959.
5. Bodey GP. Pseudomonas aeruginosa infections in cancer patients: have they gone away? Curr Opin Infect Dis 2001;14:403-407.
6. Vidal F, Mensa J, Martinez JA, Almela M, Marco F, Gatell JM, Richart C, Soriano E, Jimenez de Anta MT. Pseudomonas aeruginosa bacteremia in patients infected with HIV-1. Eur J Clin Microbiol Infect Dis 1999;18:473-477.
7. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the pulmonary complications, ICU support, and prognostic factors of hospitalized patients with HIV study. Chest 2000;117:1017-1022.
8. Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, Sanchez M, Martinez JA. Severe community-acquired pneumonia: risk factors and follow up epidemiology. Am J Respir Crit Care Med 1999;160:923-939.
9. Speert DP. Molecular epidemiology of Pseudomonas aeruginosa. Front Biosci 2002;7:354-361.
10. Diekema DJ, Pfaller MA, Jones RN. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada and Latin America for the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1999;29:595-607.
11. Rello J, Diaz E. Pneumonia in the intensive care unit. Crit Care Med 2003;31:2544-2551.
12. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-498.
13. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, Jaeschke RZ, Brun-Buisson C. Incidence and risk factors for ventilator associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-440.
14. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996;53:1711-1725.
15. Rello J, Lorente C, Diaz E, Bodi M, Boque C, Sandiumenge A, Maria Santamaria JM. Incidence, etiology and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation. Chest 2003;124:2239-2243.
16. Chastre J, Trouillet JL, Vaugnat A, Joly-Gillou ML, Clavier H, Dombret MC, Gilbert C. Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;157:1165-1172.
17. Markowicz P, Wolff M, Djedani K, Cohen Y, Chastre J, Declaux C, Merrer J, Hermen B, Veber B, Fontaine A, et al. Multicenter prospective study of ventilator associated pneumonia during acute respiratory distress syndrome: incidence, prognosis and risk factors. ARDS Study Group. Am J Respir Crit Care Med 2000;161:1942-1948.
18. Rello J, Rue M, Jubert P, Muses G, Sonora R, Valles J, Neiderman MS. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997;25:1862-1867.
19. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;159:1249-1256.
20. Craven DE. Epidemiology of ventilator associated pneumonia. Chest 2000;117:186S-187S.
21. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common source of persistent infections. Microb Immunol Dis 1999;284:1318-1322.
22. Chatzinikoloau I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000;160:501-509.
23. Chastre J, Trouillet JL. Problem pathogens Pseudomonas aeruginosa and acinetobacter. Semin Respir Infect 2000;15:287-298.
24. Santucci SG, Gobara S, Santos CR, Fontana C, Levin AS. Infections in a burn intensive care unit: experience of 7 years. J Hosp Infect 2003;53:6-13.
25. Bodey GP. Pseudomonas aeruginosa infections in cancer patients: have they gone away? Curr Opin Infect Dis 2001;14:403-407.
26. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV study. Chest 2000;117:1017-1022.
27. Sopena N, Sabria M, Pedro-Botet ML, Manterola JM, Matas L, Dominguez J, Modol JM, Tudela P, Ausia V, Foz M. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur J Clin Microbiol Infect Dis 1999;18:852-858.
28. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and P. aeruginosa. Arch Intern Med 2002;162:1849-1858.
29. Ali A. El-Sohl, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001;163:645-651.
30. Monso E, Garcia-Aymerich J, Soler N, Farrero E, Felez MA, Anto JM, Torres A. Epidemiol Infect 2003;131:799-804.
31. Srinivasan A, Wolfenden LL, Song X, Mackie K, Hartsell TL, Jones HD, Diette GB, Orens JB, Yung RC, Ross TL, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003;348:221-227.
32. Hatchette T, Gupta R, Marrie TJ. Pseudomonas aeruginosa community acquired pneumonia in previously healthy adult: case report and review of literature. Clin Infect Dis 2000;31:1349-1356.
33. Wine J. The genesis of cystic fibrosis lung disease. J Clin Invest 1999;103:309-312.
34. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
35. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-452.
36. Cystic Fibrosis Foundation Patient Registry. 2001 annual data report to the center directors. Bethesda, MD: Cystic Fibrosis Foundation; 2002.
37. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
38. Chernish RN, Aaron SD. Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 2003;9:504-508.
39. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med 2003;9:492-497.
40. Marshall BC. Cystic Fibrosis. Curr Opin Pulm Med 2003;9:484-485.
41. Ferkol TW, Look DC. Chinks in the armor of the airway: Pseudomonas infection in the cystic fibrosis lung. Am J Respir Cell Mol Biol 2001;25:11-13.
42. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23:146-158.
43. Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease, Curr Opin Pulm Med 2003;9:486-491.
44. Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002;347:1110-1111.
45. Schroeder TH, Lee MM, Yacono PW, Cannon CL, Gerceker AA, Golan DE, Pier GB. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci USA 2002;99(10):6907-6912.
46. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997;94:12088-12093.
47. Bals R, Wang X, Wu Z, Freeman T, Bafna V, Zasloff M, Wilson JM. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998;102:874-880.
48. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552-555.
49. Singh PK, Tack BF, McCray PB Jr, Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 2000;279;L799-L805.
50. Knowles MR, Robinson JM, Wood RE, Pue CA, Mentz WM, Wager GC, Gatzy JT, Boucher RC. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 1997;100:2588-2595.
51. Verkman AS, Song Y, Thiagarajah JR. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003;284:C2-C15.
52. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997;100:2810-2815.
53. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997;175:638-647.
54. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-191.
55. Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med 2002;165:911-915.
56. Mall M, Orubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-493.
57. Venkatakrishnan A, Stecenko AA, King G, Blackwell TR, Brigham KL, Christman JW, Blackwell TS. Exaggerated activation of nuclear factor-κB-β processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;23:396-403.
58. Weber AJ, Soong G, Bryan R, Saba S, Prince A. Activation of NF-κB in airway epithelial cells is dependent on CFTR trafficking and Cl-channel. Am J Physiol Lung Cell Mol Physiol 2001;281:L71-L78.
59. Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004;5:388-392.
60. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infection. Science 1999;284:1318-1322.
61. Shirtliff ME, Mader JT, Camper AK. Molecular interactions of biofilms. Chem Biol 2002;9:859-871.
62. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Science 2002;416:740-743.
63. Martin DW, Schurr MJ, Mudd MH, Govan JRW, Holloway BW, Deretic V. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci USA 1993;90(18):8377-8381.
64. Song Z, Wu H, Ciofu O, Kong KF, Hoiby N, Rygaard J, Kharazmi A, Mathee K. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol 2003;52:731-740.
65. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34:1129-1135.
66. Wolfgang MC, Jyot J, Goodman AL, Ramphal R, Lory S. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci USA 2004;101:6664-6668.
67. Ernst RK, Yi EC, Guo L, Lim KB, Burns JL, Hackett M, Miller SI. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999;286:1561-1565.
68. Bonten MJ, Bergmans DC, Speijer H, Stobberingh EE. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units: implications for infection control. Am J Respir Crit Care Med 1999;160:1212-1219.
69. Nseir S, Pompeo C, Pronnier P, Beague S, Onimus T, Saulnier F, Grandbastein B, Mathieu D, Delvallez-Roussel M, Durocher A. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, etiology and outcome. Eur Respir J 2002;20:1483-1489.
70. Visca P, Leoni L, Wilson MJ, Lamont IL. Iron transport and regulation, cell signalling and genomics: lessons from Escherichia coli and Pseudomonas aeruginosa. Mol Microbiol 2002;45:1177-1190.
71. Haussler S, Ziegler I, Lottel A, von Gotz F, Rohde M, Wehmhohner D, Saravanamuthu S, Tummler B, Steinmetz I. Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol 2003;52:295-301.
72. Spencer DH, Kas A, Smith EE, Raymond CK, Sims EH, Hastings M, Burns JL, Kaul R, Olson MV. Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol 2003;185:1316-1325.
73. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FSL, Hufnagle WO, Kowalik DJ, Lagrou M, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000;406:959-964.
74. Feldman M, Bryan R, Rajan S, Scheffler L, Brunnert S, Tang H, Prince A. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998;66:43-51.
75. Fleiszig SMJ, Evans DJ, Do N, Shin S, Vallas V, Mostov KE. Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity. Infect Immun 1997;65:2861-2867.
76. Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002;30(3):521-528.
77. Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J Clin Invest 2004;113(10):1482-1489.
78. Adamo R, Sokol S, Soong G, Gomez M, Prince A. Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and Toll-like receptor 2 as well as Toll-like receptor 5. Am J Respir Cell Mol Biol 2004;30:1-8.
79. Hauser AR, Fleiszig S, Kang PJ, Mostov K, Engel JN. Defects in type III secretion correlate with internalization of Pseudomonas aeruginosa by epithelial cells. Infect Immun 1998;66:1413-1420.
80. Gauthier A, Thomas NA, Finlay BB. Bacterial injection machines. J Biol Chem 2003;278:25273-25276.
81. Epelman S, Stack D, Bell C, Wong E, Neely GG, Krutzik S, Miyake K, Kubes P, Zbytnuik LD, Ma LL, et al. Different domains of Pseudomonas aeruginosa exoenzyme S activate distinct TLRs. J Immunol 2004;173:2031-2040.
82. Finck-Barbancon V, Goranson J, Zhu L, Sawa T, Weiner-Kronish JP, Fleiszig SM, Wu C, Mende-Mueller L, Frank DW. Exo U expression by P. aeruginosa correlates with acute cytoxicity and epithelial injury. Mol Microbiol 1997;25:547-557.
83. Finck-Barbancon V, Frank DW. Multiple domains are required for the toxic activity of Pseudomonas aeruginosa exo U. J Bacteriol 2001;183:4330-4344.
84. Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, Weiner-Kronish JP, Frank DW. Active and passive immunization with Pseudomonas V antigen protects against type III intoxication and lung injury. Nature 1999;5:392-398.
85. Sato H, Frank DW. ExoU is a potent intracellular phospholipase. Mol Microbiol 2004;53:1279-1290.
86. Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, Weiner-Kronish JP. Therapeutic administration of anti-PcrV F(ab)2 in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001;167:5880-5886.
87. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Weiner-Kronish JP. Type III secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001;183:1767-1774.
88. Passador L, Cook JM, Gambello MJ, Rust L, Iglewski BH. Expression of Pseudomonas aeruginosa virulence genes requires cell to cell communication. Science 1993;260:1127-1130.
89. Davies DJ, Prsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of bacterial biolfilm. Science 1998;280:295-298.
90. Fuqua C, Greenberg EP. Listening in on bacteria: acyl-homoserine lactone signaling. Nat Rev Mol Cell Biol 2002;3:685-695.
91. Smith RS, Iglewski BH. Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. J Clin Invest 2003;112:1460-1465.
92. Lesprit P, Faurisson F, Join-Lambert O, Roudot-Thoraval F, Foglino M, Vissuzaine C, Carbon C. Role of quorum-sensing system in experimental pneumonia due to Pseudomonas aeruginosa in rats. Am J Respir Crit Care Med 2003;167:1478-1482.
93. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416:740-743.
94. Smith RS, Kelly R, Iglewski BH, Phipps RP. The Pseudomonas auto-inducer N-(3-oxododecanoyl) homoserine lactone induces cyclooxy-genase-2 and prostaglandin E2 production in human lung fibroblasts: implications for inflammation. J Immunol 2002;169:2636-2642.
95. Tateda K, Ishii Y, Horikawa M, Matsumoto T, Miyari S, Calude Pechere J, Standiford TJ, Ishiguro M, Yamaguchi K. The Pseudomonas aeruginosa autoinducer N-3-O-HSL accelerates apoptosis in macrophages and neutrophils. Infect Immun 2003;71:5785-5793.
96. Smith RS, Fedyk ER, Springer TA, Mukaida N, Iglewski BH, Phipps RP. IL-8 production in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-B and activator protein-2. J Immunol 2001;167:366-374.
97. Smith RS, Harris SG, Phipps R, Iglewski B. The Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)homoserine lactone contributes to virulence and induces inflammation in vivo. J Bacteriol 2002;184:1132-1139.
98. Telford G, Wheeler D, Williams P, Tomkins PT, Appleby P, Sewell H, Stewart GS, Bycroft BW, Pritchard DI. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Infect Immun 1998;66:36-42.
99. Saiman L, Marshall BC, Mayer-Hamblet N, Burns JL, Quittner AL, Cibene DA, Coqquillette S, Fieberg AY, Accurso FJ, Campbell PW. Azithromycin in patients with cystic fibrosis chronically infected with P. aeruginosa. JAMA 2003;290:1749-1756.
100. Tateda K, Comte R, Pechere J, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45:1930-1933.
101. Xiao R, Kisaalita WS. Iron acquisition from transferrin and lactoferrin by Pseudomonas aeruginosa pyoverdin. Microbiology 1997;143:2509-2515.
102. Takase H, Nitanai H, Hoshino K, Otani T. Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect Immun 2000;68:1834-1839.
103. Meyer JM, Neely A, Stintzi A, Georges C, Holder IA. Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun 1996;64:518-523.
104. Vasil ML, Ochsner UA. The response of Pseudomonas aeruginosa to iron: genetics, biochemistry and virulence. Mol Microbiol 1999;34:399-413.
105. Lamont IL, Beare PA, Ochsner U, Vasil Al, Vasil ML. Siderophore-mediated signaling regulates virulence factor production in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2002;99:7072-7077.
106. Mariencheck WI, Alcorn JF, Palmer SM, Wright JR. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol 2003;28:528-537.
107. Wilson R, Pitt T, Taylor G, Watson D, MacDermot J, Sykes D, Roberts D, Cole P. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest 1987;79:221-229.
108. Denning GM, Wollenweber LA, Railsback MA, Cox CD, Stoll LL, Britigan BE. Pseudomonas pyocyanin increases interleukin-8 expression by human airway epithelial cells. Infect Immun 1998;66:5777-5784.
109. O'Malley YQ, Reszka KJ, Rasmussen GT, Abdalla MY, Denning GM, Britigan BE. The Pseudomonas secretory product pyocyanin inhibits catalase activity in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2003;285:L1077-L1086.
110. O'Malley YQ, Abdalla MY, McCormick ML, Reszka KJ, Denning GM, Britigan BE. Subcellular localization of Pseudomonas pyocyanin cytotoxicity in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2003;284:L420-L430.
111. Beattie BK, Merrill AR. In vitro enzyme activation and folded stability of Pseudomonas aeruginosa exotoxin A and its C-terminal peptide, Biochemistry 1996;35:9042-9051.
112. Yates SP, Merrill AR. A catalytic loop within Pseudomonas aeruginosa exotoxin A modulates its transferase activity. J Biol Chem 2001;276:35029-35036.
113. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, Martin TR, Wiener-Kronish JP. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999;104:743-750.
114. Kurahashi K, Ota S, Nakamura K, Nagashima Y, Yazawa T, Satoh M, Fujita A, Kamiya R, Fujita E, Baba Y, et al. Effect of lung-protective ventilation on severe Pseudomonas aeruginosa pneumonia and sepsis in rats. Am J Physiol Lung Cell Mol Physiol 2004;287:L402-L410.
115. Ernst RK, Miller SI. Peptides, pseudomonas aeruginosa, polysaccharides and lipopolysaccharides - players in the predicament of cystic fibrosis patients: response. Trends Microbiol 2000;8:250-251.
116. Boucher JC, Yu H, Mudd MH, Deretic V. Mucoid Pseudomonas aerugi nosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 1997;65:3838-3846.
117. Firoved AM, Deretic V. Microarray analysis of global gene expression in mucoid Pseudomonas aeruginosa. J Bacteriol 2003;185:1071-1081.
118. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-577.
119. Whittsett JA. Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense and repair. J Clin Invest 2002;109:565-569.
120. Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. J Clin Invest 1997;100:6-10.
121. Li JD, Dohrman AF, Gallup M, Miyata S, Gum JR, Kim YS, Nadel JA, Prince A, Basbaum CB. Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc Natl Acad Sci USA 1997;94:967-972.
122. Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB Jr, O'Neill S, McElvaney NG. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003;171:931-937.
123. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, et al. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998;95:14961-14966.
124. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998;101:2598-2605.
125. DiMango E, Zar HJ, Bryan R, Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995;96(5):2204-2210.
126. Tsai WC, Stricter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 2000;68(7):4289-4296.
127. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89(5):1478-1484.
128. Singh PK, Jia HP, Wiles K, et al. Production of β-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998;95:14961-14966.
129. Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S, Schroder JM. Mucoid P. aeruginosa, TNF-α and IL-1β, but not IL-6, induce human β-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000;22:714-721.
130. Ratner AJ, Bryan R, Weber A, Nguyen S, Barnes D, Pitt A, Gelber S, Cheung A, Prince A. Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J Biol Chem 2001;276:19267-19275.
131. Muir A, Soong G, Sokol S, Reddy B, Gomez M, van Heecheren A, Prince A. Toll like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 2004;30:627-634.
132. Lopez-Boado YS, Wilson CL, Parks WC. Regulation of matrilysin expression in airway epithelial cells by Pseudomonas aeruginosa flagellin. J Biol Chem 2001;276:41417-41423.
133. Grassme H, Kirschnek S, Riethmueller J, Riehle A, von Kurthy G, Lang F, Weller M, Gulbins E. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000;290:527-530.
134. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbims E. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001;23:20589-20596.
135. Grassme H, Jendrossek V, Riehle A, von Kurthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003;9:322-330.
136. Rajan S, Cacalano G, Bryan R, Ratner AJ, Sontich CU, van Heerckeren A, Davis P, Prince A. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors, Am J Respir Cell Mol Biol 2000;23:304-312.
137. Hotchkiss RS, Dunne WM, Swanson PE, Davis CG, Tinsley KW, Chang KC, Buchman TJ, Karl IE. Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science 2001;294:1783.
138. Jendrossek V, Grassme H, Mueller I, Lang F, Gulbins E. Pseudomonas aeruginosa -induced apoptosis involves mitochondria and stress activated protein kinases. Infect Immun 2001;69:2675-2683.
139. Thorma-Usynski S, Strenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Rollinghoff M, Bolcskei PL, Wagner M, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001;291:1544-1547.
140. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-787.
141. Speert DP, Wright SD, Silverstein SC, Math B. Functional characterization of macrophage receptors for in vitro phagocytosis of unopsonized Pseudomonas aeruginosa. J Clin Invest 1988;82:872-879.
142. Lee DJ, Cox D, Li J, Greenberg S. Rac1 and Cdc42 are required for phagocytosis, but not NF-kappaB-dependent gene expression, in macrophages challenged with Pseudomonas aeruginosa. J Biol Chem 2000;275:141-146.
143. Speert DP, Gordon S. Phagocytosis of unopsonized Pseudomonas aeruginosa by murine macrophages is a two step process requiring glucose. J Clin Invest 1992;90:1085-1090.
144. Kooguchi K, Hashimoto S, Kobayashi A, Kitamura Y, Kudoh I, Weiner-Kronish J, Sawa T. Role of alveolar macrophages in the regulation of inflammation in Pseudomonas aeruginosa pneumonia. Infect Immun 1998;66:3164-3169.
145. Cheung DOY, Halsey K, Speert DP. Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect Immun 2000;68:4585-4592.
146. Fujimoto J, Weiner-Kronish JP, Hashimoto S, Sawa T. Effects of Cl2MDP-encapsulating liposomes in a murine model of Pseudomonas aeruginosa sepsis. J Liposome Res 2002;12:239-257.
147. Ojielo CI, Cooke K, Mancuso P, Standiford TJ, Olkiewicz KM, Clouthier S, Corrion L, Ballinger MN, Toews GB, Paine R III, et al. Defective phagocytosis and clearance of Pseudomonas aeruginosa in the lung following bone marrow transplantation. J Immunol 2003;171: 4416-4424.
148. Morissette C, Francoeur C, Darmond-Zwaig C, Gervais F. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect Immun 1996;64:4984-4992.
149. Mizgerd JP. Molecular mechanisms of neutrophil recruitment elicited by bacteria in the lungs. Immunology 2002;14:123-132.
150. Kumasaka T, Doyle NA, Quinlan WM, Graham L, Doershuk CM. Role of CD11/CD18 in neutrophil emigration during acute and recurrent Pseudomonas aeruginosa induced pneumonia in rabbits. Am J Pathol 1996;148:1297-1305.
151. Qin L, Quinlan WM, Doyle NA, Graham L, Sligh JE, Takei F, Beauddet AL, Doershuk CM. The roles of CD11/CD18 and ICAM-1 in acute Pseudomonas aeruginosa-induced pneumonia in mice. J Immunol 1996;157:5016-5021.
152. Mizgerd JP, Horwitz BH, Quillen HC, Scott ML, Doershuk CM. Effects of CD 18 deficiency on the emigration of murine neutrophils during pneumonia. J Immunol 1999;163:995-999.
153. Gyeto MR, Sud S, Kendall T, Fuller JA, Newstaed MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000;165:1513-1519.
154. Usher LR, Lawson RA, Geary I, Taylor CJ, Single CD, Taylor GW, Whyle MKB. Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. J Immunol 2002;168:1861-1868.
155. Tateda K, Ishii Y, Horikawa M, Matsumoto T, Miyari S, Calude Pechere J, Standiford TJ, Ishiguro M, Yamaguchi K. The Pseudomonas aeruginosa auoinducer N-3-O-HSL accelerates apoptosis in macrophages and neutrophils. Infect Immun 2003;71:5785-5793.
156. Dunkley ML, Clancy RL, Cripps AW. A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology 1994;83:362-369.
157. Tam M, Snipes GJ, Stevenson MM. Characterization of chronic bronchopulmonary Pseudomonas aeruginonsa infection in resistant and susceptible inbred mice strains. Am J Respir Cell Mol Biol 1999;115:103-109.
158. Moser C, Hougen HP, Song Z, Rygaard J, Kharazmi A, Hoiby N. Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS 1999;107:1093-1100.
159. Moser C, Jensen PO, Kobayashi O, Hougen HP, Song Z, Rygaard J, Kharazmi A, By NH. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol 2002;127:206-213.
160. Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C, Hoiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 2000;108:329-335.
161. Nieuwenhuis ES, Matsumoto T, Exley M, Schleipman RA, Glickman J, Bailey DT, Corazza N, Colgan SP, Onderdonk AB, Blumberg RS. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002;8:588-593.
162. Beutler B. Innate immunity: an overview. Mol Immunol 2004;40:845-859.
163. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
164. Lorenz E, Chemotti DC, Vandal K, Tessier PA. Toll-like receptor 2 represses nonpilus adhesin-induced signaling in acute infections with the Pseudomonas aeruginosa pilA mutant. Infect Immun 2004;72:4561-4569.
165. Madrazo DR, Tranguch SL, Marriott I. Signaling via Toll-like receptor 5 can initiate inflammatory mediator production by murine osteoblasts. Infect Immun 2003;71:5418-5421.
166. Backhed F, Normark S, Schweda EK, Oscarson S, Richter-Dahlfors A. Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes Infect 2003;5:1057-1063.
167. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002;3:354-359.
168. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001;414(6866):920-924.
169. Strom MS, Lory S. Structure-function and biogenesis of the type IV pili. Annu Rev Microbiol 1993;47:565-596.
170. Becker MN, Diamond G, Verghese MW, Randell SH. CD-14-dependent lipopolysaccharide induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000;275:29731-29736.
171. Barton GM, Medzhitov R. Toll-like receptor signaling pathways, Science 2003;300:1524-1525.
172. Skerrett SJ, Liggitt HD, Hajjar AM, Wilson CB. Cutting edge: myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus. J Immunol 2004;172:3377-3381.
173. Power MR, Peng Y, Maydanski E, Marshall JS, Lin TJ. The development of early host response to Pseudomonas aeruginosa lung infection is critically dependent on MyD88 in mice. J Biol Chem 2004;279:49315-49322.
174. Morissette C, Francoeur C, Darmond-Zwaig C, Gervais F. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect Immun 1996;64:4984-4992.
175. Gosselin D, DeSanctis J, Boule M, Skamene E, Matouk C, Radzioch D. Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995;63:3272-3278.
176. Chen GH, Reddy RC, Newstead NW, Tateda K, Kyasapura BL, Standiford TJ. Intrapulmonary TNF gene therapy reverses sepsis induced suppression of lung antibacterial host defense. J Immunol 2000;165: 6496-6503.
177. Lee J, Del Sorbo L, Khine AA, de Azavedo J, Low DE, Bell D, Uhlig S, Slutsky AS, Zhang H. Modulation of bacterial growth by tumor necrosis factor-α in vitro and in vivo. Am J Respir Crit Care Med 2003;168:1462-1470.
178. Rezaiguia S, Garat C, Delclaux C, Meignan M, Fleury J, Legrand P, Matthay MA, Jayr C. Acute bacterial pneumonia in rats increases alveolar epithelial fluid clearance by a tumor necrosis factor-alpha-dependent mechanism. J din Invest 1997;99:325-335.
179. Skerrett SJ, Martin TR, Chi EY, Peschon JJ, Mohler KM, Wilson CB. Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa. Am J Physiol 1999;276:L715-L727.
180. Schultz MJ, Rijneveld W, Floruin S, Edwards CK, Dinarello CA, Van der Pol T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2002;282:L285-L290.
181. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-474.
182. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997;275:206-209.
183. Grobmyer SR, Lin E, Lowry SF, Rivadeneira DE, Potter S, Barie PS, Nathan CF. Elevation of IL-18 in human sepsis. J Clin Immunol 2000;20:212-215.
184. Schultz MJ, Knapp S, Florquin S, Pater J, Takeda K, Akira S, van der Poll T. Interleukin-18 impairs the pulmonary host response to Pseudomonas aeruginosa. Infect Immun 2003;71:1630-1634.
185. Massion PP, Inoue H, Richman-Eisenstat J, Grunberger D, Jorens PG, Housset B, Pittet JF, Wiener-Kronish JP, Nadel JA. Novel Pseudomonas product stimulates interleukin-8 production in airway epithelial cells in vitro. J Clin Invest 1994;93:26-32.
186. DiMango E, Zar HJ, Bryan R, Prince A. Diverse Pseudomonas aeruginosa gene product stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995;96:2204-2210.
187. Mori N, Oishi K, Sar B, Mukaida N, Nagatake T, Matsushima K, Yamamoto N. Essential role of transcription factor nuclear factor-kappaB in regulation of interleukin-8 gene expression by nitrite reductase from Pseudomonas aeruginosa in respiratory epithelial cells. Infect Immun 1999;67:3872-3878.
188. Lei D, Lancaster JR, Joshi MS, Nelson MS, Stroltz D, Bagby GJ, Odom, Shellito JE, Kolls JK. Activation of alveolar macrophages and lung host defenses using transfer of interferon-gamma gene. Am J Physiol 1997;272:L852-L859.
189. Johansen HK, Hougen HP, Rygaard J, Hoiby N. Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996;103:212-218.
190. Schultz MJ, Rijneveld AW, Speelman P, van Deventer SJ, van der Poll T. Endogenous interferon-gamma impairs bacterial clearance from lungs during Pseudomonas aeruginosa pneumonia. Eur Cytokine Netw 2001;12:39-44.
191. Walley KRN, Lukacs NW, Standiford TJ, Stieter RM. Kunkel SL. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996;64:4733-4738.
192. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of MIP-2 and TNF. J Immunol 1995;155:2222-2227.
193. Steinhauser ML, Hogaboam CM. Kunkel SL, Lukacs NW, Streiter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-399.
194. Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Kirchner HL, Berger M. Prolonged inflammatory response to acute P. aeruginosa challenge in IL-10 knockout mice. Am J Respir Crit Care Med 2002;165:1176-1181.
195. Sawa T, Corry DB, Cropper MA, Ohara M, Kurahashi K, Weiner-Kronish JP. IL-10 improves lung injury and survival in Pseudomonas aeruinosa pneumonia. J Immunol 1997;159:2858-2866.
196. Jain-Vora S, LeVine AM, Chroneos Z, Ross GF, Hull WM, Whitsett JA. lnterleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa. Infect Immun 1998;66:4229-4236.
197. Speert DP, Wright SD, Silverstein SC, Mah B. Functional characterization of macrophage receptors for in vitro phagocytosis of unopsonized Pseudomonas aeruginosa. J Clin Invest 1988;82:872-879.
198. Yamaguchi T, Hirakata Y, Izumikawa K, Miyazaki Y, Maesaki S, Tomono K, Yamada Y, Kohno S, Kamhiri S. Prolonged survival of mice with Pseudomomas aeruginosa induced sepsis induced by rIL-12 modulation of IL-10 and IFN-γ. J Med Microbiol 2000;49:701-709.
199. Hopken EL. Bao N, Gerard N, Gerard C. The C5a chemoattractant receptor mediates mucosal defense to infection. Nature 1996;383:86-89.
200. Younger JG, Shankar-Sinha S, Mickiewcz M, Brinkman AS, Valencia GA, Sarma JV, Younkin EM, Syandiford TJ, Zetoune FS, Ward PA. Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am J Respir Cell Mol Biol 2003;29:432-438.
201. Forman HJ, Torres M. Reactive oxygen species and cell signaling: respi ratory burst in macrophage signaling. Am J Respir Crit Care Med 2002;166:S4-S8.
202. Sadikot RT, Zeng H, Yull FE, Li B, Cheng DS, Kernodle DS, Jansen ED, Contag CH, Segal BH, Holland SM, et al. p47(phox) deficiency impairs NF-kappaB activation and host defense in Pseudomonas pneumonia. J Immunol 2004;172:1801-1808.
203. Fang FC. Host/pathogen interactions: mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997;99:2818-2825.
204. Webert KE, Vanderzwan J, Duggan M, Scott JA, McCormack DG, Lewis JE, Mehta S, Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia. Crit Care Med 2000;28:2397-2405.
205. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-777.
206. Park PW, Pier GB, Preston MJ, Gold berger O, Fitzgerald ML, Bernfield M. Syndecan-1 shedding is enhanced by LasA, secreted virulence factor of Pseudomonas aeruginosa. J Biol Chem 2000;275:3057-3064.
207. Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rose-John S, Massague J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996;271:11376-11382.
208. Park PW, Reizes O, Bernfiled M. Cell surface heparan sulfate proteoglycans selective regulators of ligand-receptor encounters. J Biol Chem 2000;275:29923-29926.
209. Park PW, Pier GB, Hinkes MT, Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001;411:98-102.
210. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-962.
211. LeVine A, Whitsett JA. Pulmonary collectins and innate host defense of the lung. Microbes Infect 2001;3:161-166.
212. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D orchestrate innate immunity in the lung. J Clin Invest 2002;109:707-712.
213. Postle AD, Mander A, Reid KB, Wang JY, Wright SM, Moustaki M, Warner JO. Deficient hydrophilic lung surfactant phospholipid molecular species in cystic fibrosis. Am J Respir Cell Mol Biol 1999;20:90-98.
214. Meyer KC, Sharma A, Brown R, Weatherby M, Moya FR, Lewandoski J, Zimmerman JJ. Function and composition of pulmonary surfactant-derived fatty acid profiles are altered in young adults with cystic fibrosis. Chest 2000;118:164-174.
215. Bufler P, Schmidt B, Schikor D, Bauernfeind A, Crouch EC, Griese M. Surfactant protein A and D differently regulate the immune response to nonmucoid Pseudomonas aeruginosa and its lipopolysaccharide. Am J Respir Cell Mol Biol 2003;28:249-256.
216. Miyamura K. Leigh LE, Lu J, Hopkin J, Lopez BA, Reid KB. Surfactant protein D binding to alveolar macrophages. Biochem J 1994;3000:237-242.
217. Kuan SF, Persson A, Parghi D, Crouc E. Lectin-mediated interactions of surfactant protein D with alveolar macrophages. Am J Respir Cell Mol Biol 1994;10:430-436.
218. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR. Surfactant protein-A deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998;19:700-708.
219. Lim BL, Wang JY, Holmskov U, Hoppe HJ, Reid KB. Expression of the carbohydrate recognition domain of surfactant protein D and demonstration of its binding to lipopolysaccharide of gram-negative bacteria. Biochem Biophys Res Commun 1994;202:1674-1680.
220. Restrepo CI, Dong Q, Savov J, Mariencheck WI, Wright JR. Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Respir Cell Mol Biol 1999;21:576-585.